Clinical Trial Update: A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease [Phase 3]

View source ↗

Summary

A Phase 3 randomized study and a long-term open-label study evaluating SYR-472 (25 mg) in patients with type 2 diabetes mellitus and severe renal impairment or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYR-472

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-11-04